SCHEMBL3523768

SCHEMBL3523768

CS(=O)(=O)N(c1ncc(C(=O)c2cccs2)c(N)n1)C1CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.42
CDK1 P06493 4/20 0.42
CDK4 P11802 3/20 0.42
CCND1 P24385 3/20 0.42
CACNA2D1 P54289 1/20 0.37
ALOX15 P16050 2/20 0.35
PSMD14 O00487 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MMP2 P08253 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PBK Q96KB5 4/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34
CCNA2 P20248 1/20 0.34
CCNB2 O95067 1/20 0.34
CCNE2 O96020 1/20 0.34
CCNB1 P14635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521307 0.90 CDK2 (0.38) CDK2CDK1CDK4CCND1CACNA2D1
SCHEMBL4350415 0.85 BTK (0.42) CDK2CDK1CDK4CCND1SLC6A2
SCHEMBL3519635 0.84 CDK2 (0.45) CDK2CDK1CDK4CCND1SLC6A2
SCHEMBL3522557 0.82 CDK2 (0.54) CDK2CDK1CDK4CCND1SLC6A2
SCHEMBL4350208 0.82 CDK1 (0.47) CDK2CDK1CDK4CCND1SLC6A2
SCHEMBL4361247 0.81 CDK1 (0.42) CDK2CDK1CDK4CCND1ALDH1A1
SCHEMBL4350748 0.80 CDK1 (0.39) CDK2CDK1CDK4CCND1MAPT
SCHEMBL4352658 0.80 CDK1 (0.41) CDK2CDK1CDK4CCND1SLC6A2
SCHEMBL4352681 0.80 CDK1 (0.52) CDK2CDK1CDK4CCND1CCNA2
SCHEMBL4352515 0.80 CDK1 (0.65) CDK2CDK1CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK2 4/4885CDK1 6/4885CDK4 1/4885
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives CDK4, CDK1, CDK2 CDK2 3/4885CDK1 2/4885CDK4 1/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK2 3/4885CDK1 6/4885CDK4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.